πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,148 results for β€œGang” Clear

  1. Lenvatinib, Belzutifan, Lenvatinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2Ξ± related Genetic Alterations

    phase 3 small molecule active

    1 trial

  2. Letrozole

    The First People's Hospital of Lianyungang

    Polycystic Ovary Syndrome

    phase 3 small molecule completed

    1 trial

  3. Megestrol（YiningοΌ‰

    The First People's Hospital of Lianyungang

    Stage III Esophageal Squamous Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  4. Metformin plus pioglitazone

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  5. Methylprednisolone pulse

    The First People's Hospital of Lianyungang

    Glomerulonephritis, IGA

    phase 3 small molecule terminated

    1 trial

  6. Methylprednisolone sodium succinate

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  7. Mimetic granules of Yiqi-Wenjing prescriptions

    The First People's Hospital of Lianyungang

    Chemotherapy-induced Peripheral Neuropathy

    phase 3 small molecule active

    1 trial

  8. Mitoxantrone Hydrochloride Liposome

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  9. N-Acetylcysteine

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathies

    phase 3 small molecule completed

    1 trial

  10. N-Acetylcysteine (NAC) Treatment

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathy

    phase 3 small molecule active

    1 trial

  11. Nedaplatin

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 3 small molecule completed

    1 trial

  12. Nimotuzumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  13. Normal Saline

    The First People's Hospital of Lianyungang

    Postoperative Sleep Disturbance

    phase 3 small molecule active

    1 trial

  14. Osimertinib

    The First People's Hospital of Lianyungang

    Non-small Cell Carcinoma

    phase 3 small molecule active

    1 trial

  15. Oxaliplatin

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  16. Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  17. PREDNISOLONE, CORTISONE ACETATE, FLUDROCORTISONE, Gohibic, TRIAMCINOLONE, PREDNISONE, DEXAMETHASONE, HYDROCORTISONE, METHYLPREDNISOLONE, IFX-1 placebo is formulated as PBS (150 mM sodium chloride, 10 mM sodium phosphate, pH 7.0) with 0.05% polysorbate 80. IFX-1 placebo is diluted in sterile 0.9% sodium chloride to the required concentration and volume. This diluent is a commercial product not accompanying IFX-1 placebo., BETAMETHASONE

    InflaRx GmbH

    ulcerative pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  18. Paclitaxel

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  19. Paclitaxel or docetaxel + Cisplatin or carboplatin

    The First People's Hospital of Lianyungang

    Uterine Cervical Neoplasms

    phase 3 small molecule active

    1 trial

  20. Paclitaxel, Cisplatin Plus 5-FU (TCF)

    The First People's Hospital of Lianyungang

    Esophageal Cancer Stage IIB

    phase 3 other active

    1 trial

  21. Pembrolizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  22. Placebo matching to spesolimab

    Boehringer Ingelheim

    Pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  23. Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  24. Realgar-Indigo naturalis formula

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources